Form 8-K - Current report:
SEC Accession No. 0001193125-25-147011
Filing Date
2025-06-25
Accepted
2025-06-25 16:39:03
Documents
19
Period of Report
2025-06-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d887947d8k.htm   iXBRL 8-K 30962
2 EX-1.1 d887947dex11.htm EX-1.1 211759
3 EX-5.1 d887947dex51.htm EX-5.1 8641
4 EX-99.1 d887947dex991.htm EX-99.1 8299
5 EX-99.2 d887947dex992.htm EX-99.2 8513
9 GRAPHIC g887947dsp.jpg GRAPHIC 4342
10 GRAPHIC g887947g0625000859296.jpg GRAPHIC 4173
11 GRAPHIC g887947g0625000913768.jpg GRAPHIC 4230
  Complete submission text file 0001193125-25-147011.txt   471407

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA cdtx-20250624.xsd EX-101.SCH 2836
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE cdtx-20250624_lab.xml EX-101.LAB 17995
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cdtx-20250624_pre.xml EX-101.PRE 11252
21 EXTRACTED XBRL INSTANCE DOCUMENT d887947d8k_htm.xml XML 3643
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Filer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36912 | Film No.: 251074109
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)